DAW1033B2 in Obstructive Sleep Apnea
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Insomnia Sleep Studies, Pulmonary, Pulmonary |
| Therapuetic Areas: | Psychiatry / Psychology, Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 21 - 65 |
| Updated: | 3/27/2019 |
| Start Date: | September 15, 2017 |
| End Date: | November 15, 2019 |
Effect of DAW1033B2 on Obstructive Sleep Apnea
Obstructive sleep apnea (OSA) is common and has major health implications but treatment
options are limited. OSA patients show a marked reduction in upper airway (UA) dilator muscle
activity at sleep onset and this phenomenon leads to increased collapsibility of UA compared
to normal subjects. In this protocol the investigators will test the effect of DAW1033B2
administered before sleep on OSA phenotype traits and OSA severity during sleep.
options are limited. OSA patients show a marked reduction in upper airway (UA) dilator muscle
activity at sleep onset and this phenomenon leads to increased collapsibility of UA compared
to normal subjects. In this protocol the investigators will test the effect of DAW1033B2
administered before sleep on OSA phenotype traits and OSA severity during sleep.
Inclusion Criterion:
- OSA: AHI > 15
Exclusion Criteria:
- Any medical condition other than well controlled hypertension, diabetes,
hyperlipidemia
- Any medication known to influence breathing, sleep/arousal or muscle physiology.
- Claustrophobia.
- Inability to sleep supine.
- Allergy to lidocaine, Oxymetazoline HCl, DAW1033D.
- Individuals with underlying cardiac disease, such as arrhythmias.
- Individuals taking psychiatric medications, or any of the studied medications for
medical care.
- History of seizures
- For women: Pregnancy.
- History of panic disorder / hyperventilation syndrome / Attention
deficit-hyperactivity disorder (ADHD) / autism
We found this trial at
1
site
Click here to add this to my saved trials
